Nuvectra (NVTRQ) Stock Price, News & Analysis

Company Overview

Nuvectra Corp is a medical device company focused on the development and commercialization of neuromodulation therapies for chronic pain management. The company’s flagship product, the Freedom® Spinal Cord Stimulation (SCS) System, is designed to deliver electrical pulses to the spinal cord via implantable leads and an implantable pulse generator (IPG). The system incorporates wireless recharging capabilities and physician-programmable stimulation parameters, enabling tailored pain relief for patients who have not responded adequately to conservative treatments such as medication or physical therapy.

Nuvectra received FDA approval for its Freedom SCS System in 2015 and subsequently launched the product in the United States through a direct sales force and partnerships with select distributors. The company also pursued regulatory clearances and limited market access in international jurisdictions. In April 2018, Nuvectra filed for Chapter 11 bankruptcy protection and subsequently sold its assets. Its remaining equity now trades on the OTC Pink market under the ticker NVTRQ, reflecting the company’s transformed status post-restructuring.

Throughout its operational history, Nuvectra built a leadership team with experience in medical technology, regulatory affairs, and clinical research to support product development and patient outcomes. Although the company’s restructuring curtailed ongoing R&D activities, the Freedom SCS System represented a notable advancement in implantable neuromodulation platforms, particularly in its focus on programmability and patient comfort. Nuvectra’s legacy in the spinal cord stimulation space continues to inform new approaches to chronic pain therapy within the broader medical device industry.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.0150 to $0.0150
• 52-Week Range: $0.01 to $4.30
• Volume: 382,600 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVTRQ Stock Analysis - Frequently Asked Questions

How have NVTRQ shares performed this year?

Nuvectra's stock was trading at $0.0150 at the beginning of the year. Since then, NVTRQ stock has increased by 0.0% and is now trading at $0.0150.

How were Nuvectra's earnings last quarter?

Nuvectra Corporation (OTCMKTS:NVTRQ) issued its earnings results on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.01. The firm had revenue of $14.22 million for the quarter, compared to analysts' expectations of $12.38 million.

How do I buy shares of Nuvectra?

Shares of NVTRQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 10/29/2018
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:NVTRQ
• Previous Symbol: NASDAQ:NVTRV
• CIK: 1648893
• Web: www.nuvectramed.com
• Phone: 214-474-3103
• Fax: N/A
• Employees: 197
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A